Psoriasis Screening: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There is no consensus | There is no consensus on screening for psoriasis among the general population but there are screening methods, which can be used for screening for psoriasis. These screening methods include the psoriasis screening tool (PST) and [[genetic testing]]. | ||
==Screening== | ==Screening== | ||
Revision as of 19:18, 31 July 2017
|
Psoriasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Psoriasis Screening On the Web |
|
American Roentgen Ray Society Images of Psoriasis Screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]
Overview
There is no consensus on screening for psoriasis among the general population but there are screening methods, which can be used for screening for psoriasis. These screening methods include the psoriasis screening tool (PST) and genetic testing.
Screening
Genetic screening for psoriasis
- The strong association of psoriasis with genetics gives way to screening for this disease via genetic testing.
- HLA Class I antigens (HLA-B13, HLA-B57, HLA-B39, HLA-Cw6, HLACw7) have been known to be associated with psoriasis and psoriatic arthritis.[1]
- HLA-B13, -B16, and its splits -B38 and -B39, B17, and Cw6 are associated with psoriasis, with or without arthritis.
- Early screening combined with early treatment can help prevent disease progression.
- A sample for genetic testing is usually taken from a cheek swab.
Psoriasis screening tool (PST)
- The Psoriasis Screening Tool (PST) consists of eight close ended questions with a "yes" or "no" response with typical images of skin, nail and scalp changes in psoriasis included with respective questions.[2]
- The questions distinguish individuals with psoriasis from individuals without the disease in an outpatient setting.
- A similar questionnaire exists for psoriatic arthritis, called the Psoriasis Epidemiology Screening Tool (PEST).[3]
References
- ↑ Gladman DD, Farewell VT (2003). "HLA studies in psoriatic arthritis: current situation and future needs". J. Rheumatol. 30 (1): 4–6. PMID 12508382.
- ↑ Dominguez PL, Assarpour A, Kuo H, Holt EW, Tyler S, Qureshi AA (2009). "Development and pilot-testing of a psoriasis screening tool". Br. J. Dermatol. 161 (4): 778–84. doi:10.1111/j.1365-2133.2009.09247.x. PMID 19566664.
- ↑ "Psoriasis Epidemiology Screening Tool (PEST): A Report from the GRAPPA 2009 Annual Meeting | The Journal of Rheumatology".